Results 91 to 100 of about 5,951 (176)

CYP3A-Mediated Metabolism of Zastaprazan in Humans and Associated Drug-Drug Interactions. [PDF]

Pharmaceutics
Cao KJ, Fu L, Sun YC, Meng J, Huang Q, Deng DC, Hu HT, Han ZH, Guo G, Zhou X, Chen XY.   +10 more
europepmc   +1 more source

Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development. [PDF]

CPT Pharmacometrics Syst Pharmacol
Chen X, Lin Z.
europepmc   +1 more source

Pharmacometric modeling of opioid disposition in pregnancy: a systematic review of PopPK and PBPK approaches, model limitations, and future directions. [PDF]

Front Pharmacol
Zaidi SS, Abbasi MY, Ganapaneni S, Quinney SK.   +3 more
europepmc   +1 more source

Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment. [PDF]

Front Pharmacol
Pokladyuk A, Voronova V, Helmlinger G, Peskov K, Kosinsky Y.   +4 more
europepmc   +1 more source

Developmental age and clinical illness drive <i>in vivo</i> variability of CYP1A2 ontogeny and caffeine metabolism in preterm neonates. [PDF]

Front Pharmacol
Wang MC, Sealey VA, Rahman M, Ngugama M, Trolat A, Wybenga-Groot L, Moran MF, Dinh J, Lewis TR.   +8 more
europepmc   +1 more source

Physiologically-Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach. [PDF]

Clin Transl Sci
Khier S, El Gaaloul M, Tarning J, Abla N.   +3 more
europepmc   +1 more source

Guiding a Diclofenac Sodium Dual-Release Sustained Formulation Development Through In Vitro-In Vivo Relationship Based on Physiologically Based Pharmacokinetics. [PDF]

Pharmaceutics
Wang Q, Guo P, Hu T, Li L, Zhu T, Pan Y, Xiang X, Wang J.   +7 more
europepmc   +1 more source

Virtual Bioequivalence Assessment of Long-acting Injectable Suspensions Using PBPK Modeling: Part 1. Impact of particle Size on Formulation Variability. [PDF]

AAPS J
Morris NM, Djehizian A, Mittapelly N, Telaprolu KC, Holland BW, McNally K, Polak S, Jamei M, Alam K, Tsakalozou E, Donnelly M, Feng K, Bois FY.   +12 more
europepmc   +1 more source

Is a Clinical Trial With a Non-Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK. [PDF]

Clin Pharmacol Ther
Dong J, Moir A, Pepin X, Lowe E, Hopkins S, Tang W, Zhou D.   +6 more
europepmc   +1 more source

Machine Learning Meets Pharmacokinetics: A Comparative Analysis of Predictive Models for Plasma Concentration-Time Profiles. [PDF]

CPT Pharmacometrics Syst Pharmacol
Jost F, Giegerich C, Grebner C, Matter H, Cordes H.   +4 more
europepmc   +1 more source